anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open label study, which means that all parties including the study doctor, the healthy volunteer and the sponsor plus his designees will know at all times which treatment the volunteer is in. This is a 4-way cross over trial, which means that every volunteer will be sequentially subjected to 4 different treatments.There are 4 treatment sequences defined: ABCD, BDAC, CADB and DCBA. Treatment sessions are organized in such a way that between successive intakes of TMC278 a period of 14 days is respected. Treatment A is the reference, showing the levels of TMC278 in blood without any intake of omeprazole. These data points will be compared with blood levels of TMC278 when TMC278 is being administered 1.5 hours after intake of omeprazole (Treatment B) or with blood levels of TMC278 when being administered 12 hours after intake of omeprazole (Treatment C). Treatment B will be the comparator of Treatment D, in order to reveal whether doubling the dose of TMC278 (50 mg q.d. used in Treatment D) can circumvent the reduction of TMC278 levels when being co-administered with omeprazole, if applicable. In each session, an extensive investigation of the levels of TMC278 in the blood circulation is planned. Levels of TMC278 will be assessed at 16 different time points, i.e. before administration of TMC278, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 16, 24, 48, 72, 120 and 168 hours after intake of TMC278. During all treatments, the acidity in the stomach (called intragastric pH) will be monitored during a 24-hour period on the day of TMC278 intake. Standard Safety assessments (blood biochemistry and haematology, urine analysis, ECG, pulse rate and blood pressure) will be performed on Day1, 2 and 8 in Treatment A and on Day-5, 1, 2, 8 in Treatment B, C and D. Treatment A: 25mg TMC278 in the morning of Day1; Treatment B: 25mg TMC278 in the morning of Day1 and 20mg omeprazole in the morning from Day-5 through Day2 (7 days in total); Treatment C: same as treatment B, but omeprazole is taken in the evening; Treatment D: same as treatment B, but 50mg omeprazole is taken instead of 25mg. All intakes are oral. In Treatment B, C and D, the intake of omeprazole is witnessed by site staff on Days -5, -3, -2 and -1
The present disclosure relates to the treatment of transfusion dependence and anemia in patients with myelodysplastic syndrome (MDS). The present disclosure relates to methods of using novel biomarkers to treat transfusion dependence and anemia in an MDS patient in need thereof. The present disclosure also relates to methods of identifying MDS patients suitable for treatment with a splicing modulator and/or predicting or monitoring treatment efficacy in an MDS patient. In some embodiments, the methods disclosed herein comprise determining at least the ratio of aberrant junction to canonical junction TMEM14C transcripts (TMEM14C AJ/CJ ratio) in the patient. In some embodiments, the methods disclosed herein comprise administering a therapeutically effective amount of a splicing modulator (e.g., Compound 1) based on the patient's TMEM14C AJ/CJ ratio. Therapeutic uses and compositions are also disclosed.
With limited treatment options, cachexia remains a major challenge for patients with cancer. Characterizing the interplay between tumor cells and the immune microenvironment may help identify potential therapeutic targets for cancer cachexia. Herein, we investigate the critical role of macrophages in potentiating pancreatic cancer induced muscle wasting via promoting TWEAK (TNF-like weak inducer of apoptosis) secretion from the tumor. Specifically, depletion of macrophages reverses muscle degradation induced by tumor cells. Macrophages induce non-autonomous secretion of TWEAK through CCL5/TRAF6/NF-κB pathway. TWEAK promotes muscle atrophy by activating MuRF1 initiated muscle remodeling. Notably, tumor cells recruit and reprogram macrophages via the CCL2/CCR2 axis and disrupting the interplay between macrophages and tumor cells attenuates muscle wasting. Collectively, this study identifies a feedforward loop between pancreatic cancer cells and macrophages, underlying the non-autonomous activation of TWEAK secretion from tumor cells thereby providing promising therapeutic targets for pancreatic cancer cachexia.
Optimum dosage varies with the severity of the symptoms and the response of the individual patient. When a satisfactory response is obtained, dosage should be reduced to the smallest amount needed to maintain the remission. The larger portion of the total daily dose may be taken at bedtime. In some patients, a single dose at bedtime may be sufficient. In general, lower dosages are recommended for elderly patients.

Chlordiazepoxide and amitriptyline hydrochloride tablets 10 mg/25 mg are recommended in an initial dosage of 3 or 4 tablets daily in divided doses; this may be increased to 6 tablets daily as required. Some patients respond to smaller doses and can be maintained on 2 tablets daily.

Chlordiazepoxide and amitriptyline hydrochloride tablets 5 mg/12.5 mg in an initial dosage of 3 or 4 tablets daily in divided doses may be satisfactory in patients who do not tolerate higher doses.
PROBLEM TO BE SOLVED: To prepare a new adjuvant having high safety to a vaccinated animal, having high adjuvant activity and useful for vaccine by including a specific oligosaccharide fatty acid amide or a specific oligosaccharide fatty acid ester. SOLUTION: This new adjuvant is prepared by including (A) an oligosaccharide fatty acid amide (e.g. oleoyl chitosan) where an oligosaccharide having gluconsamine as a monosaccharide unit and a fatty acid are combined through an amide bond or (B) an oligosaccharide fatty acid ester (e.g. maltohexaose oleate) where an oligosaccharide having at least one of glucose, galactose and mannose as a monosaccharide unit and a fatty acid are combined through an ester bond. The sugar chain of the oligosaccharides of the ingredients A and B is preferably made up with 3-99 monosaccharides. The adjuvant may be an aqueous suspension or the like including the ingredient A or the ingredient B in a content of 0.3-5 wt./vol.% based on the weight of the aqueous medium of the suspension.
The fusion of electroencephalography (EEG) with machine learning is transforming rehabilitation. Our study introduces a neural network model proficient in distinguishing pre- and post-rehabilitation states in patients with Broca's aphasia, based on brain connectivity metrics derived from EEG recordings during verbal and spatial working memory tasks. The Granger causality (GC), phase-locking value (PLV), weighted phase-lag index (wPLI), mutual information (MI), and complex Pearson correlation coefficient (CPCC) across the delta, theta, and low- and high-gamma bands were used (excluding GC, which spanned the entire frequency spectrum). Across eight participants, employing leave-one-out validation for each, we evaluated the intersubject prediction accuracy across all connectivity methods and frequency bands. GC, MI theta, and PLV low-gamma emerged as the top performers, achieving 89.4%, 85.8%, and 82.7% accuracy in classifying verbal working memory task data. Intriguingly, measures designed to eliminate volume conduction exhibited the poorest performance in predicting rehabilitation-induced brain changes. This observation, coupled with variations in model performance across frequency bands, implies that different connectivity measures capture distinct brain processes involved in rehabilitation. The results of this paper contribute to current knowledge by presenting a clear strategy of utilizing limited data to achieve valid and meaningful results of machine learning on post-stroke rehabilitation EEG data, and they show that the differences in classification accuracy likely reflect distinct brain processes underlying rehabilitation after stroke.
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study designed to assess the potential effect of topically applied 3.75% imiquimod cream on atrial ectopy in actinic keratosis (AK) patients. Candidates for study participation will begin screening procedures up to 28 days prior to enrollment. Qualified subjects shall be admitted to the CRU on Day -1 for baseline evaluations and will be randomized to one of two possible treatment sequences. Each subject will receive both the active 3.75% imiquimod cream and the matching placebo in a randomized crossover fashion with a 2-week washout in between each treatment. The application area is the entire face (exclusive of nares, vermilion, periocular areas and ears) or balding scalp. Atrial ectopy will be monitored for 24 hours at Baseline (Day -1; prior to the first dose of study medication), and at the conclusion of each 14-day treatment period using a continuous 12-lead digital Holter recorder.

Adverse events, concomitant medication use, study medication accountability, and subject compliance will be reviewed at each visit.
Chronic infection with hepatitis C virus (HCV) is a common cause of complications such as liver cirrhosis and hepatocellular carcinoma (HCC). It is one of the most significant infectious diseases worldwide, posing a substantial health burden. Since the introduction of direct-acting antiviral agents (DAAs), the treatment landscape has undergone a revolution. HCV infection is curable, and the treatment is safe and well tolerated. Due to the availability of this effective therapeutic option, the World Health Organization (WHO) set an ambitious goal in 2015 to eliminate Hepatitis C by 2030, a goal that the German government also embraced in 2016. The key tasks involve identifying previously undiagnosed cases and ensuring they receive antiviral treatment. Addressing at-risk populations through specific measures, including micro-elimination projects and population-wide campaigns, is essential to achieving the WHO's target both in Germany and globally.
In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate hours, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, for genital area cleaning based on the gender of newborns, women will be provided to perform the procedure on the model appropriate to the gender of their babies. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
A lemon and honey mask and a production method thereof are characterized in that a formula comprises honey, lemon juice, oatmeal, a vitamin E capsule and a container. After face cleaning, the self-produced mask is evenly applied to the face, and eyes and lips are avoided. The face is relaxed to absorb nutrition from the mask. The face is cleaned with clear water after about 20 min. The mask is required to be applied once a week. The honey is a water-soluble moisturizer and can tightly lock moisture of the skin and provide an excellent moisturizing effect, so that the skin becomes soft and full of elasticity.
The purpose of the present invention is to provide a liquid fermentation method for fungi of Amauoderma rudis and obtained products thereof, which is beneficial to the scale application to pharmaceutical industry and food industry. Amauoderma rudis has a scientific name of wrinkle cover Amauoderma rudis, and gains the name because bloody secretions are generated in wound positions when the sporophore of the sporophore is young. A culture medium of the liquid fermentation production method of Amauoderma rudis of the present invention comprises the components of the proportion by weight: 1 to 2% of maize flour, 2 to 5% of bean cake powder, 2 to 5% of glucose, 0.2% of yeast cream, 0.1% of KHP2O4 and water as the rest. The pH value is 5.5, and the components are sterilized for 20 minutes at the temperature of 121 DEG C under the pressure of 0.1MPa. The culture condition comprises: 100 to 120 ml of culture medium is filled into a 250 ml shake flask, the shake flask is placed on a rotary shaking table in 150 to 200 rpm to be cultured for 5 days at the temperature from 28-1 DEG C to 28 +1 DEG C after the culture medium is inoculated, and the culture medium is filtered to collect mycelia. Animal experiments prove that liquid fermentation products of Amauoderma rudis have supernormal bioactivity and have important application prospects of resisting consenescence and improving immune functions.
Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease, which is characterized by decreased platelet count and skin and mucosal bleeding. ITP is a kind of disease with increased platelet destruction and impaired platelet production caused by autoimmunity. Conventional treatment of adult ITP includes first-line glucocorticoid and immunoglobulin therapy, second line TPO and TPO receptor agonist, splenectomy and other immunosuppressive treatments (such as rituximab, vincristine, azathioprine, etc.). ITP is one of the most common hemorrhagic diseases. At present, the treatment response of ITP is not good, and a considerable number of patients need drug maintenance treatment, which seriously affects the quality of life of patients and increases the economic burden of patients. Longitudinal Cohort allows to describe the long-term clinical characteristics of pediatric ITP patients, to study the benefit-risk balance of treatments, including the growing development of targeted therapies and to analyze the prognostic factors and attempts to establish prognostic models.

The study will include pediatric patients diagnosed with primary immune thrombocytopenia in the investigating hospitals, and collect basic information, diagnostic and treatment information from medical records. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.
Hepatocellular carcinoma (HCC) stands as a formidable global health challenge due to its prevalence, marked by high mortality and morbidity rates. This cancer type exhibits a multifaceted etiology, prominently linked to viral infections, non-alcoholic fatty liver disease, and genomic mutations. The inherent heterogeneity of HCC, coupled with its proclivity for developing drug resistance, presents formidable obstacles to effective therapeutic interventions. Autophagy, a fundamental catabolic process, plays a pivotal role in maintaining cellular homeostasis, responding to stressors such as nutrient deprivation. In the context of HCC, tumor cells exploit autophagy, either augmenting or impeding its activity, thereby influencing tumorigenesis. This comprehensive review underscores the dualistic role of autophagy in HCC, acting as both a pro-survival and pro-death mechanism, impacting the trajectory of tumorigenesis. The anti-carcinogenic potential of autophagy is evident in its ability to enhance apoptosis and ferroptosis in HCC cells. Pertinently, dysregulated autophagy fosters drug resistance in the carcinogenic context. Both genomic and epigenetic factors can regulate autophagy in HCC progression. Recognizing the paramount importance of autophagy in HCC progression, this review introduces pharmacological compounds capable of modulating autophagy-either inducing or inhibiting it, as promising avenues in HCC therapy.
AIM: Patients undergoing haemodialysis have reduced muscle strength and impaired activities of daily living (ADL). We examined possible relationship between difficult ADL and corresponding muscle weakness in elderly haemodialysis patients.
METHODS: This was a single-centre, cross-sectional study. Patient-reported ADL difficulty was examined using a questionnaire in six ADL using upper limbs (eating, grooming and dressing) and lower limbs (bathing, toileting and locomotion). We measured six muscle strengths by dynamometers of shoulder flexion, shoulder abduction, elbow flexion, handgrip, hip abduction and knee extension. The muscle strength with the lowest Z-score was considered as the weakest muscle strength for the patient.
RESULTS: The six scores of ADL difficulty were all inversely associated with the six muscle strengths in the 81 total participants of whom 71 individuals (87.7%) had any ADL difficulty. Among the six measurements of muscle strength, handgrip strength showed the highest associations with all ADL difficulties. In 25 patients who perceived that the most difficult ADL was an activity using upper limbs, the common weakest muscle strengths were the hip abduction, handgrip and elbow flexion. In 44 patients who perceived that the most difficult ADL was an activity using lower limbs, knee extension was the most prevalent weakest muscle strength.
CONCLUSION: This study suggested preferential relationship between the most difficult ADL and corresponding muscle weakness in elderly haemodialysis patients. This finding may be useful in prevention and treatment.
Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
Among all medical conditions, patients with heart failure report significantly poorer quality of life than do the other patients (1). The existing literature describes a wide range of negative emotions common among patients with heart failure; these include everything from depression, anxiety, submission and helplessness to a profound sense of "discord and brokenness." The prevalence of depression, ranging from 11% to 25% among heart disease outpatients and 35% to 70% among those who are hospitalized (2). By comparison, the overall percentage of the population suffering from depression is about 6.6%. Psychological depression appears to be an important predictor of rehospitalization among persons who have been admitted with coronary artery disease (3). In addition, depression in patients with heart failure was found to be associated with the course of the disease and its prognosis. For example, it was found that in patients with heart failure, a diagnosis of Major Depression was correlated with a higher rate of mortality (4), and depressive symptoms predicted short-term worsening of heart failure symptoms (5). The reduction in quality of life that was also found to be common in patients with heart failure is also a prognostic factor for repeated hospitalizations and death (6).

The high prevalence of distress among the population of patients with heart failure, along with the broad impact on the patient's quality of life, requires attention to detail and the implementation of interventions aimed at reducing levels of distress. Very few studies describe interventions aimed at alleviating distress in patients with heart failure. Cognitive Behavioral Therapy is reported to improve both the functional and emotional levels of these patients, resulting in the relief of their symptoms of depression. Using relaxation, Bio-Feedback devices have also achieved a reduction in depression of heart failure patients. Research testing the efficacy of psychological treatment using the interpersonal approach now is being performed; it is funded by the U.S. NIMH and is, at present, in the initial recruitment stages (National Institute of Mental Health, 2010). Studies examining the beneficial effects of group therapy are few in number and most of them utilize a Cognitive Behavioral approach. This therapeutic orientation has been found to be effective when the disease is moderate or the prognosis is favorable. However, outcomes tend to differ greatly when it comes to patients in advanced stages of the condition. These patients are also confronted with fundamental aspects of their own mortality. A large body of literature about psychological interventions for these patients exists. Many of these interventions are based on an Existential Approach aimed at facilitating responses to the unique distress of patients in an advanced stage of the disease (7).

This study examines the contribution of a group therapy program based on the Existential Approach aimed at reducing distress in patients with heart failure.
Debate is present concerning the optimal level of humidification for obstructive sleep apnea (OSA) patients who need continuous positive airway pressure (CPAP) therapy. Recent evidence has shown that using a heated breathing tube to increase the amount of humidification that can be delivered has decreased patient side effects, increased subjective sleep quality and decreased subjective symptom scores. Anecdotal evidence exists, in the form of clinical observation, when ThermoSmart® technology is utilized during CPAP titration, patients laboratory titrated pressure may in fact prove to be lower. The possibility exists, on a titration night, patients potentially may experience an adverse response to the positive airway pressure which manifests as increased airway resistance and inflammation necessitating higher CPAP pressures to overcome upper airway resistance and flow limitation. Therefore, we hypothesize the delivery of higher levels of humidity might reduce the nasal airway resistance during the titration night, reducing the overall positive airway pressure requirements. The goal is to investigate this phenomenon to find if a reduction in pressure is necessary and if so to what degree. Patients who are titrated on Continuous Positive Airway Pressure devices with ThermoSmart® technology will have lower titrated pressures than those who are titrated using conventional humidification.
PURPOSE:To obtain a cosmetic for preventing chapped skin, by blending an oil-in-water type dispersion system containing a natural material having surface active action and a humectant with a liposome water dispersion system prepared by the use of a interstelluar liquid while stirring in such a way that dispersion particles exist in both the systems. CONSTITUTION:An oil-in-water type dispersion system containing 0.01-10.0wt.% (based on sum of cosmetic) natural material (e.g. elastin or collagen) having surface active action and 0.005-40.0wt.% humectant (e.g. hyaluronic acid or chondroitin sulfuric acid) is blended with a liposome water dispersion system prepared by treating 0.01-10.0wt.% intercelluar lipid (e.g. phospholipid, glycolipid or cholesterols) with ultrasonic wave while maintaining the blend at <= a temperature to make the interface in a liquid state and stirring by agitating force as mildly as possible for a short time to give a skin cosmetic. The cosmetic can prevent drying of skin for a long period and raise restoring effects on keratin layer of skin.
Adult septic patients admitted to the Intensive Care Unit (ICU) or Intermediary Medical Unit in Karolinska University Hospital will be recruited within 72 hours from start of symptoms.

Other than fulfilling the definition for sepsis-3, patients need to be equipped with an arterial catheter to be eligible for inclusion. After informed consent (from next of kin when applicable) baseline blood samples are drawn from existing catheter and the subject is given a bolus dose of 20umol/kg 13C-labeled lactate in 20 ml isotonic saline. After this a total of 14 blood samples á 2 ml is drawn in the following 120 minutes. All blood samples are centrifuged and stored in -800 C until analysis. After all subjects have been included sampled are thawed and analyzed for content of endogenous and labeled lactate. Through analysis between their relationship the lactate production and consumption can be quantified.